

Bone Metastasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/B3A7FA3CB8E8EN.html>

Date: August 2022

Pages: 98

Price: US\$ 2,000.00 (Single User License)

ID: B3A7FA3CB8E8EN

Abstracts

Bone Metastasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Drugs In Development, 2022, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.

Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 3, 10, 1, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 9, 1 and 1 molecules, respectively.

Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).

The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bone Metastasis

(Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Bone Metastasis - Overview

Bone Metastasis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bone Metastasis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bone Metastasis - Companies Involved in Therapeutics Development

Bone Metastasis - Drug Profiles

Bone Metastasis - Dormant Projects

Bone Metastasis - Discontinued Products

Bone Metastasis - Product Development Milestones

Featured News & Press Releases

Aug 31, 2021: Qilu Pharmaceutical Co Ltd received the notice of acceptance

Dec 15, 2020: Luye Pharma Group : Voluntary announcement denosumab injection (LY01011) commenced phase III clinical trial in China

Oct 28, 2020: CSPC Pharmaceutical Group : Voluntary announcement first patient dosed in the phase 1 clinical trial of investigational new drug "ALMB-0168"

Sep 15, 2020: CSPC Pharmaceutical Group: Voluntary Announcement Investigational New Drug "ALMB-0168" obtains clinical trial approval in China

Nov 27, 2019: CSPC Pharmaceutical: Submission Of clinical trial application for investigational first-in-class new drug ALMB-0168 in Australia

Jan 05, 2018: NeuClone Discloses Details of its Fifth Product: A Biosimilar Candidate for Prolia/XGEVA (Denosumab)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Bone Metastasis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Bone Metastasis - Dormant Projects, 2022
Bone Metastasis - Dormant Projects, 2022 (Contd..1)
Bone Metastasis - Dormant Projects, 2022 (Contd..2)
Bone Metastasis - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Bone Metastasis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Bone Metastasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/B3A7FA3CB8E8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B3A7FA3CB8E8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

